• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[关于德国新型口服抗凝剂（NOAC）长期治疗患者急性冠状动脉综合征院前治疗共识声明的评论]

[Comments on the German consensus statement on prehospital treatment of acute coronary syndrome in patients under long-term treatment with novel oral anticoagulants (NOAC)].

作者信息

Schneck Emmanuel, Hamm Christian W, Schneck Franziska, Wolter Jan Sebastian, Dirkmann Daniel, Koch Christian, Sander Michael

机构信息

Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Universitätsklinikum Gießen und Marburg, Standort Gießen, Justus-Liebig-Universität Gießen, Rudolf-Buchheim-Straße 7, 35392, Gießen, Deutschland.

Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI e. V.), Berlin, Deutschland.

出版信息

Anaesthesist. 2021 Sep;70(9):785-788. doi: 10.1007/s00101-021-00943-6. Epub 2021 Mar 24.

DOI:10.1007/s00101-021-00943-6
PMID:33760939
Abstract

Despite an increasing number of patients suffering from an acute coronary syndrome under novel oral anticoagulant therapy, specific treatment recommendations for anticoagulation are still lacking. For this reason, the German Society of Cardiology and the German Association of Interdisciplinary Intensive Care and Emergency Medicine developed a consensus statement for the treatment of these patients with the aim to summarize the current evidence and to increase the safety of this special patient group.

摘要

尽管接受新型口服抗凝治疗的急性冠状动脉综合征患者数量不断增加，但针对抗凝治疗仍缺乏具体的治疗建议。因此，德国心脏病学会和德国跨学科重症监护与急诊医学协会制定了一份针对这些患者治疗的共识声明，旨在总结当前证据并提高这一特殊患者群体的安全性。

相似文献

1
[Comments on the German consensus statement on prehospital treatment of acute coronary syndrome in patients under long-term treatment with novel oral anticoagulants (NOAC)].[关于德国新型口服抗凝剂（NOAC）长期治疗患者急性冠状动脉综合征院前治疗共识声明的评论]
Anaesthesist. 2021 Sep;70(9):785-788. doi: 10.1007/s00101-021-00943-6. Epub 2021 Mar 24.
2
[Prehospital management of acute coronary syndrome in patients on long-term direct oral anticoagulant treatment].长期接受直接口服抗凝剂治疗的急性冠状动脉综合征患者的院前管理
Anaesthesist. 2020 Feb;69(2):108-116. doi: 10.1007/s00101-019-00710-8. Epub 2019 Dec 4.
3
Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.口服抗凝剂治疗患者严重出血的管理：急诊医学心脏研究与教育集团-国际多学科严重出血共识小组2018年10月20日会议纪要
Crit Pathw Cardiol. 2019 Sep;18(3):143-166. doi: 10.1097/HPC.0000000000000181.
4
Novel oral anticoagulants in acute coronary syndrome.新型口服抗凝药物在急性冠状动脉综合征中的应用。
Int J Cardiol. 2013 Sep 10;167(6):2449-55. doi: 10.1016/j.ijcard.2012.08.014. Epub 2012 Sep 16.
5
Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.新型及新兴口服抗凝药在急性冠脉综合征二级预防中的作用
Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13.
6
High platelet reactivity--the challenge of prolonged anticoagulation therapy after ACS.高血小板反应性——ACS 后延长抗凝治疗的挑战。
Thromb Haemost. 2013 May;109(5):799-807. doi: 10.1160/TH12-08-0582. Epub 2013 Feb 21.
7
Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: a systematic review of the literature.普通肝素和低分子量肝素在非ST段抬高型急性冠状动脉综合征中的最佳抗凝持续时间：文献系统评价
Int J Cardiol. 2014 Dec 15;177(2):461-6. doi: 10.1016/j.ijcard.2014.09.105. Epub 2014 Sep 30.
8
Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?急性冠状动脉综合征无房颤患者口服三联疗法的作用如何？
Curr Vasc Pharmacol. 2018;16(5):427-436. doi: 10.2174/1570161116666180117105339.
9
Cost effectiveness of anticoagulation in acute coronary syndromes.急性冠状动脉综合征中的抗凝治疗成本效益。
Pharmacoeconomics. 2012 Apr;30(4):303-21. doi: 10.2165/11589290-000000000-00000.
10
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.新型口服抗凝药物联合或不联合抗血小板治疗急性冠脉综合征：系统评价和荟萃分析。
Eur Heart J. 2013 Jun;34(22):1670-80. doi: 10.1093/eurheartj/eht049. Epub 2013 Mar 6.

引用本文的文献

1
Pretreatment With Unfractionated Heparin in ST-Elevation Myocardial Infarction—A Propensity Score Matching Analysis.ST段抬高型心肌梗死患者应用普通肝素预处理——一项倾向评分匹配分析
Dtsch Arztebl Int. 2024 Dec 13;121(25):833-839. doi: 10.3238/arztebl.m2024.0212.
2
[Preclinical loading in patients with acute chest pain and acute coronary syndrome - PRELOAD survey].[急性胸痛和急性冠状动脉综合征患者的临床前负荷 - PRELOAD 调查]
Med Klin Intensivmed Notfmed. 2024 Oct;119(7):529-537. doi: 10.1007/s00063-023-01087-8. Epub 2023 Nov 30.
3
[Stocked medications in emergency medical service vehicles staffed by physicians-is prehospital treatment according to current guidelines possible?].

本文引用的文献

1
[Prehospital management of acute coronary syndrome in patients on long-term direct oral anticoagulant treatment].长期接受直接口服抗凝剂治疗的急性冠状动脉综合征患者的院前管理
Anaesthesist. 2020 Feb;69(2):108-116. doi: 10.1007/s00101-019-00710-8. Epub 2019 Dec 4.
2
The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism.2019年欧洲心脏病学会急性肺栓塞诊断和管理指南。
Eur Heart J. 2019 Nov 1;40(42):3453-3455. doi: 10.1093/eurheartj/ehz726.
3
Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials.
[配备医生的急救车辆中的储备药品——按照现行指南进行院前治疗是否可行？]
Notf Rett Med. 2022 May 13:1-10. doi: 10.1007/s10049-022-01036-6.
维生素K拮抗剂与直接口服抗凝剂联合抗血小板治疗用于房颤患者经皮冠状动脉介入治疗或急性冠状动脉综合征后的双联或三联治疗：随机对照试验的荟萃分析
Clin Cardiol. 2019 Sep;42(9):839-846. doi: 10.1002/clc.23224. Epub 2019 Jul 9.
4
Association of Parenteral Anticoagulation Therapy With Outcomes in Chinese Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome.肠外抗凝治疗与非 ST 段抬高型急性冠状动脉综合征行经皮冠状动脉介入治疗的中国患者结局的相关性。
JAMA Intern Med. 2019 Feb 1;179(2):186-194. doi: 10.1001/jamainternmed.2018.5953.
5
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).2017年欧洲心脏病学会（ESC）ST段抬高型急性心肌梗死患者管理指南：欧洲心脏病学会（ESC）ST段抬高型急性心肌梗死患者管理工作组
Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.
6
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
7
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.阿哌沙班与华法林在伴有心房颤动和心脏瓣膜病患者中的比较：来自心房颤动患者阿哌沙班减少卒中和其他血栓栓塞事件（ARISTOTLE）试验的结果。
Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23.
8
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.心房颤动患者经皮冠状动脉介入治疗中的抗凝和抗血小板治疗。
Am J Cardiol. 2014 Jul 1;114(1):70-8. doi: 10.1016/j.amjcard.2014.03.060. Epub 2014 Apr 24.
9
Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome.比较三种当代出血风险评分在急性冠状动脉综合征中的预测有效性。
Eur Heart J Acute Cardiovasc Care. 2012 Sep;1(3):222-31. doi: 10.1177/2048872612453924.
10
Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography.首次冠状动脉造影检查的心房颤动患者的冠状动脉疾病发生率和严重程度。
PLoS One. 2011;6(9):e24964. doi: 10.1371/journal.pone.0024964. Epub 2011 Sep 21.